TY - JOUR
T1 - Pursuing quality in the application of bladder cancer quality of life research
AU - Mohamed, N. E.
AU - Gilbert, F.
AU - Lee, C. T.
AU - Sfakianos, J.
AU - Knauer, C.
AU - Mehrazin, R.
AU - Badr, H.
AU - Wittmann, D.
AU - Downs, T.
AU - Berry, D.
AU - Given, B.
AU - Wiklund, P.
AU - Steineck, G.
N1 - Publisher Copyright:
© 2016 - IOS Press and the authors. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Patient-reported outcomes (PRO), including health-related quality of life (HRQOL) measures, represent important means for evaluating patients' health outcomes and for guiding health care decisions made by patients, practitioners, investigators, and policy makers. In spite of the large number of studies examining HRQOL in patients with bladder cancer, very few review articles investigated this topic. Because these review studies report mixed results, incorporating bladder cancer HRQOL measures into standard urological practice is not a viable option. In this non-systematic review of the literature and commentary we note some general concerns regarding PRO research, but our primary focus is on the HRQOL methodology within the context of two types of bladder cancer: muscle invasive and non-muscle invasive bladder cancer. Considering bladder cancer HRQOL as the interaction of four areas of the assessment process (i.e., what model of HRQOL to choose, what instruments are available to fit the choice, how interpretation of the resulting data fits the model, and how to derive some utility from the chosen model) and the two types of disease (i.e., muscle invasive and non-muscle invasive) may move us toward a better understanding of bladder cancer HRQOL. Establishing a useful model of perceived general health or specific symptoms is the first and most important step in developing the responsive bladder cancer HRQOL measures necessitated by clinical settings.
AB - Patient-reported outcomes (PRO), including health-related quality of life (HRQOL) measures, represent important means for evaluating patients' health outcomes and for guiding health care decisions made by patients, practitioners, investigators, and policy makers. In spite of the large number of studies examining HRQOL in patients with bladder cancer, very few review articles investigated this topic. Because these review studies report mixed results, incorporating bladder cancer HRQOL measures into standard urological practice is not a viable option. In this non-systematic review of the literature and commentary we note some general concerns regarding PRO research, but our primary focus is on the HRQOL methodology within the context of two types of bladder cancer: muscle invasive and non-muscle invasive bladder cancer. Considering bladder cancer HRQOL as the interaction of four areas of the assessment process (i.e., what model of HRQOL to choose, what instruments are available to fit the choice, how interpretation of the resulting data fits the model, and how to derive some utility from the chosen model) and the two types of disease (i.e., muscle invasive and non-muscle invasive) may move us toward a better understanding of bladder cancer HRQOL. Establishing a useful model of perceived general health or specific symptoms is the first and most important step in developing the responsive bladder cancer HRQOL measures necessitated by clinical settings.
KW - Bladder cancer
KW - Conceptual model of quality of life
KW - Design and development of bladder cancer quality of life measures
KW - Health-related quality of life
KW - Muscle invasive bladder cancer
KW - Nonmuscle invasive bladder cancer
KW - Patient-reported outcomes
KW - Quality of life assessments
UR - http://www.scopus.com/inward/record.url?scp=85020277990&partnerID=8YFLogxK
U2 - 10.3233/BLC-160051
DO - 10.3233/BLC-160051
M3 - Review article
AN - SCOPUS:85020277990
SN - 2352-3727
VL - 2
SP - 139
EP - 149
JO - Bladder Cancer
JF - Bladder Cancer
IS - 2
ER -